Adarsh Nimborkar

@adarsh.nimborkar.sebi.ia.7271

Nagpur

8+ Years of experience

SEBI Registration INA000019789

I'm Adarsh Nimborkar, with over 8 years of experience in finance, specializing in market research, options trading and portfolio management. Based in Nagpur, Maharashtra, I hold a Master of Business Administration in Finance and multiple National Institute of Securities Markets certifications, and I focus on data-drive ... Read more

Trade Ideas

Opinions

Followers

112k

Expertise

Quantitative

Growth

Technical

Index Strategies

Market Commentary

Futures & Options

Technical Analysis

Trade Facts

Total Trades

Missed Trades

Profit Trades

Accuracy

Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 5th Nov

Blue Jet Healthcare Ltd Company Fundamental Analysis

BLUEJET Blue Jet Healthcare Ltd is an Indian pharmaceutical intermediate and specialty chemicals manufacturer supplying products to global pharmaceutical companies. Its key business segments include contrast media intermediates used in diagnostic imaging, pharmaceutical intermediates, APIs and artificial sweeteners such as saccharin. Q2 FY27 results, announced on 5 November 2026, showed a strong recovery. Standalone revenue from operations increased 127.1% year-on-year to ₹375.74 crore, compared with ₹165.48 crore in Q2 FY26. Net profit increased 96.6% to ₹102.52 crore, while profit before tax nearly doubled to ₹137.39 crore. For H1 FY27, revenue reached ₹668.86 crore and net profit stood at ₹180.78 crore. However, operating margin declined to approximately 31.6% from 33.2% a year earlier, indicating that profitability did not grow as quickly as revenue. Valuation and outlook: The latest available market data places the share price around ₹543, with market capitalisation of approximately ₹9,400–10,000 crore and a trailing P/E of around 40–43x. ROE is approximately 19–20%, and debt-to-equity is very low at around 0.03, indicating a relatively strong balance sheet. The company also raised approximately ₹800 crore through a Qualified Institutional Placement (QIP) to support its expansion plans. Overall: Blue Jet Healthcare has demonstrated a strong Q2 recovery, healthy profitability and low financial leverage. Its specialised product portfolio and global customer relationships are positives. However, the stock still trades at a premium valuation, and investors should monitor margin sustainability, customer concentration and returns generated from the QIP-funded expansion.

622

shared an insight ⚡️ 5th Nov

Hariom Pipe Industries Ltd Company Analysis

HARIOMPIPE Hariom Pipe Industries Ltd is an Indian manufacturer of steel pipes, tubes and structural products used in infrastructure, construction, agriculture, housing and industrial applications. Its product portfolio includes ERW black pipes, galvanised pipes, hollow sections, billets and value-added steel products. Q2 FY27 results, announced on 4 November 2026, were very strong. Consolidated revenue from operations increased 65.1% year-on-year to ₹554.60 crore, compared with ₹335.87 crore in Q2 FY26. EBITDA grew 59.2% to ₹67.99 crore, while net profit increased approximately 142.7% to ₹25.28 crore. Basic EPS rose from ₹3.36 to ₹8.16. Sequentially, revenue increased 29.2% and net profit grew 52.3% compared with Q1 FY27. However, EBITDA margin was 12.3%, slightly below 12.7% in the year-ago quarter, indicating that profit growth also benefited from lower relative expenses and other factors rather than a major margin expansion. An important operational development is that the company's Perundurai manufacturing unit in Tamil Nadu, which had been temporarily suspended following pollution-control directions in April 2026, resumed operations on 13 July 2026 after the closure directions were suspended. This had affected Q1 performance, so the Q2 recovery partly reflects normalisation of operations. The latest Q2 results are encouraging, but the stock's valuation should be assessed against its current market price, debt, working-capital requirements and the sustainability of its earnings. Key growth drivers include infrastructure spending, expansion in water and housing projects, higher steel-pipe demand and increased manufacturing capacity. Overall Hariom Pipe has delivered strong Q2 revenue and profit growth, with the restart of its Tamil Nadu facility supporting operational recovery. However, the margin has not expanded year-on-year, and the Q2 performance should not be extrapolated without checking H1 cash flows, debt and capacity utilisation.

659

shared an insight ⚡️ 4th Nov

Awfis Space Solutions Ltd Company Analysis

AWFIS Awfis Space Solutions Ltd is one of India's leading flexible workspace and coworking operators. It provides managed offices, coworking spaces, enterprise workspaces, virtual offices and allied facility-management services. Its customers include startups, SMEs, large corporates and Global Capability Centres (GCCs). The company operates through a combination of coworking and managed aggregation models, allowing it to expand its network without funding all fit-out costs itself. Q2 FY27 results, announced on 3 November 2026, showed healthy growth. Consolidated revenue from operations increased 19.6% year-on-year to ₹438.7 crore. On a normalised basis, including actual rent adjustments for finance leases, revenue grew 26% to ₹451 crore. Cash EBITDA increased 45% to ₹49 crore, with the cash EBITDA margin improving to 10.8% from 9.4% in Q2 FY26. Net profit rose approximately 93% to ₹30.8 crore. For H1 FY27, normalised revenue increased 30% to ₹888 crore, cash EBITDA grew 40% to ₹93 crore and net profit more than doubled to ₹55 crore. Operational performance is also encouraging. Awfis reported more than 25,000 seats sold in H1 FY27, with 84.1% occupancy in mature centres. Its network covered 270 centres and approximately 188,000 seats, including operational and under-fit-out locations. The company also secured a mandate for more than 1,000 employees from a Fortune 500 company in Chennai. Valuation and outlook: The stock was trading around ₹241 on 3 November 2026. Its long-term growth drivers include corporate outsourcing of office infrastructure, GCC expansion, premium workspace demand and increasing enterprise contracts. Overall: Awfis is demonstrating strong revenue growth, improving cash EBITDA margins and increasing enterprise demand. Its asset-light managed aggregation model is a positive, but lease commitments and cash-flow generation remain critical.

877

What are the top stock recommendations by Adarsh Nimborkar?

Adarsh Nimborkar regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include BLUEJET, HARIOMPIPE and AWFIS. Explore Adarsh Nimborkar's complete list of posts and trade views on their StockGro profile.

How can I follow Adarsh Nimborkar's latest investment insights?

You can follow Adarsh Nimborkar's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is Adarsh Nimborkar's investment strategy?

Adarsh Nimborkar follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has Adarsh Nimborkar been a SEBI-registered Research Analyst (RA)?

Adarsh Nimborkar has been a SEBI-registered Research Analyst and have 8+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see Adarsh Nimborkar's past performance and stock picks?

You can check Adarsh Nimborkar's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact Adarsh Nimborkar for stock market advice?

For stock market guidance from Adarsh Nimborkar, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is Adarsh Nimborkar's track record in predicting market movements?

Adarsh Nimborkar has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for Adarsh Nimborkar?

Adarsh Nimborkar is a SEBI-registered Research Analyst with the SEBI Registration INA000019789. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.

Be Financially Free with StockGro